Abstract:Introduction: Conventional oral formulations can be difficult to swallow for patients with dysphagia, children, and the elderly. A new pharmaceutical form containing a combination of ibuprofen/pseudoephedrine designed to provide easier administration and more flexible dose adjustment while maintaining similar pharmacokinetic profile to other conventional formulations already on the market was developed. The objective of this study was to evaluate the bioequivalence of a fixed oral combination of 400 mg ibuprofen and 60 mg pseudoephedrine granules for oral solution, compared with a reference market standard formulated in soft capsules after single dose administration. Methods: An open, randomized, single dose, two-period, crossover trial was conducted. Subjects were randomly assigned to receive either 1 sachet of granules for oral solution (400 mg/60 mg – Test product), or 2 soft capsules with liquid content of SpaltGrippal® (200 mg/30 mg - Reference product) under fasting conditions. For the evaluation of bioequivalence, the 90% CI of log-transformed values were calculated for the ratios Test vs Reference for AUC(0-t) and Cmax of ibuprofen (racemic) and (1S,2S)-pseudoephedrine and then compared to the corresponding acceptance ranges. Safety and tolerability were assessed during the clinical period and one week after the last dose. Results: Bioequivalence was demonstrated for both Cmax and AUC(0-t) of pseudoephedrine, as well as for the total exposure of ibuprofen, while the Cmax of ibuprofen slightly exceeded the upper acceptance limit by approximately 6%. For both actives, Tmax was lower with the granule’s formulation. The overall safety and tolerability of the study medications were identical Conclusions: Although the bioequivalence criteria between Test and Reference product were not completely met, the new formulation of ibuprofen/pseudoephedrine granules for oral solution is able to provide a therapeutic equivalence to conventional solid forms, ensuring a more convenient administration, faster onset of analgesia for the patient without altering its total exposure.

Sustained Release Bilayer Tablet of Ibuprofen and Phenylephrine Hydrochloride: Preparation and Pharmacokinetics in Beagle Dogs

Study on Preparation of Levetiracetam Sodium Extended-release Tablet and It's Pharmacokinetics in Beagle Dogs

Study on the Bioavailability and Pharmacokinetics of Guaiphenesin Sustained Release Tablets in Beagle Dogs

Preparation, Characterization and Pharmacokinetics Evaluation of the Compound Capsules of Ibuprofen Enteric-Coated Sustained-Release Pellets and Codeine Phosphate Immediate-Release Pellets

A Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Lvpuweima Sustained-Release Tablet in the Treatment of Common Cold

Preparation and in vitro characterization of thermosensitive and mucoadhesive hydrogels for nasal delivery of phenylephrine hydrochloride

Food interactions observed in a pharmacokinetic investigation comparing two marketed cold preparations (BNO1016 and ELOM-080) after administration to male beagle dogs

In vitro evaluation and pharmacokinetics in dogs of solid dispersion pellets containing Silybum marianum extract prepared by fluid-bed coating.

Study on in Vivo Pharmacokinetics and Relative Bioavailability of Cefprozil Dispersible Tablet in Beagle Dogs

Pharmacokinetics of Oral Administration of 2, 3, 5, 4'-Tetrahydroxystilbene-2-o-β-d-glucoside from Polygonum Multiflorum in Beagle Dogs

Bioequivalence of two tablet formulations of cefpodoxime proxetil in beagle dogs

Solid Dispersion Tablets of Breviscapine with Polyvinylpyrrolidone K30 for Improved Dissolution and Bioavailability to Commercial Breviscapine Tablets in Beagle Dogs.

Ibuprofen and pseudoephedrive hydrochloride as granules for oral solution. A comparative pharmacokinetic study

Comparative single-dose pharmacokinetics of sildenafil after oral and rectal administration in healthy beagle dogs

Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs

Preparation and in vitro-in vivo Correlation in Beagle Dogs of Hawthorn Leaves Flavonoids Sustained-release Tablets

Plasma concentration of sibutramine hydrochloride in beagle dog assayed by LC-MS and study on its pharmacokinetics

Core-shell tablets designed for modified and sequential release of ibuprofen and rabeprazole

Mucoadhesive bilayered tablets for buccal sustained release of flurbiprofen

Development of Novel Tamsulosin Pellet-Loaded Oral Disintegrating Tablet Bioequivalent to Commercial Capsule in Beagle Dogs Using Microcrystalline Cellulose and Mannitol

Preparation and Characterization of Ibuprofen Containing Nano-Embedded-Microparticles for Pulmonary Delivery